Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: A large case cohort study

Hepatology International

Volumn 4, Issue 1, 2010, Pages 396-405

  Carr, Brian I ^a   Pancoska, Petr ^b   Branch, Robert A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE;

ARTICLE; ASCITES; CANCER SURVIVAL; CASE STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; PATIENT ASSESSMENT; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE;

EID: 77949656874     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-009-9157-7     Document Type: Article

References (47)

1. KR El-Serag 2007 Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2557 2576 10.1053/j.gastro.2007.04.061 17570226 (Pubitemid 46890874)
2. SJ Cho JH Yoon SS Hwang, et al. 2007 Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol 22 1226 1231 10.1111/j.1440-1746.2007.04914.x 17498220 (Pubitemid 47222656)
3. K Okuda T Ohtsuki H Obata, et al. 1985 Natural history of hepatocellular carcinoma and prognosis in relation to treatment Cancer 56 918 928 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E 1:STN:280:DyaL2M3lsVaqtw%3D%3D 2990661
4. Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751-755
5. Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840-845
6. JM Llovet J Fuster J Bruix 2004 The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma Liver Transpl 10 S115 S120 10.1002/lt.20034 14762851
7. JM Llovet C Bru J Bruix 1999 Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 329 338 10.1055/s-2007-1007122 1:STN:280:DyaK1Mvks1Grsg%3D%3D 10518312
8. R Tateishi H Yoshida S Shiina, et al. 2005 Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients Gut. 54 419 425 10.1136/gut.2003.035055 1:STN:280:DC%2BD2M%2FotFKjtg%3D%3D 15710994 (Pubitemid 40299102)
9. S Chevret JC Trinchet D Mathieu, et al. 1999 A new prognostic classification for predicting survival in patients with hepatocellular carcinoma J Hepatol 31 133 141 10.1016/S0168-8278(99)80173-1 1:STN:280: DyaK1MzltFGkuw%3D%3D 10424293 (Pubitemid 29287619)
10. TW Leung AM Tang B Zee, et al. 2002 Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients Cancer. 94 1760 1769 10.1002/cncr.10384 11920539 (Pubitemid 34241115)
11. K Omagari S Honda Y Kadokawa, et al. 2004 Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma J Gastroenterol Hepatol 19 805 811 10.1111/j.1440-1746.2004.03350.x 15209629 (Pubitemid 38981404)
12. I Levy M Sherman 2002 Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto Gut. 50 881 885 10.1136/gut.50.6.881 1:STN:280:DC%2BD383ntFKgtw%3D%3D 12010894 (Pubitemid 34539054)
13. E Giannini D Risso F Botta, et al. 2004 Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems J Intern Med 255 399 408 10.1046/j.1365-2796.2003.01284.x 1:STN:280:DC%2BD2c%2FntValuw%3D%3D 14871465 (Pubitemid 38315282)
14. JA Marrero RJ Fontana A Barrat, et al. 2005 Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort Hepatology 41 707 716 10.1002/hep.20636 15795889 (Pubitemid 40462931)
15. YH Huang CH Chen TT Chang, et al. 2005 Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery J Gastroenterol Hepatol 20 765 771 10.1111/j.1440-1746.2005. 03746.x 15853992 (Pubitemid 40733373)
16. A Grieco M Pompili G Caminiti, et al. 2005 Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre Gut. 54 411 418 10.1136/gut.2004.048124 1:STN:280:DC%2BD2M%2FotFKjsA%3D%3D 15710992 (Pubitemid 40299100)
17. S Pascual P Zapater J Such, et al. 2006 Comparison of staging systems to predict survival in hepatocellular carcinoma Liver Int 26 673 679 10.1111/j.1478-3231.2006.01282.x 16842323 (Pubitemid 43983884)
18. K Kondo K Chijiiwa M Nagano, et al. 2007 Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma Hepatogastroenterology 54 1534 1538 17708292
19. TI Huo HC Lin CY Hsia, et al. 2007 The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey Am J Gastroenterol 102 1920 1930 10.1111/j.1572-0241.2007.01370.x 17573792 (Pubitemid 47301534)
20. CS Georgiades E Liapi C Frangakis, et al. 2006 Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization J Vasc Interv Radiol 17 1619 1624 17057003
21. M Minagawa I Ikai Y Matsuyama, et al. 2007 Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13, 772 patients in Japan Ann Surg 245 909 922 10.1097/01.sla.0000254368. 65878.da 17522517 (Pubitemid 46809293)
22. H Chung M Kudo S Takahashi, et al. 2007 Review of current staging systems for hepatocellular carcinoma Hepatol Res 37 S210 S215 10.1111/j.1872-034X.2007. 00187.x 1:CAS:528:DC%2BD2sXhtlCns7jF 17877485
23. Guglielmi A, Ruzzenente A, Pachera S, et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008;103(3):597-604
24. A Pawarode N Voravud V Sriuranpong, et al. 1998 Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients Am J Clin Oncol 21 386 391 10.1097/00000421-199808000-00014 1:STN:280:DyaK1cznt1entg%3D%3D 9708639 (Pubitemid 28366909)
25. L Llado J Virgili J Figueras, et al. 2000 A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization Cancer. 88 50 57 10.1002/(SICI)1097- 0142(20000101)88:1<50::AID-CNCR8>3.0.CO;2-I 1:STN:280: DC%2BD3c%2Fos1Onsg%3D%3D 10618605 (Pubitemid 30027678)
26. CB O'Suilleabhain RT Poon JL Yong, et al. 2003 Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma Br J Surg 90 325 331 10.1002/bjs.4045 12594668 (Pubitemid 36324112)
27. T Yamasaki T Kimura F Kurokawa, et al. 2005 Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy J Gastroenterol 40 70 78 10.1007/s00535-004-1494-7 1:CAS:528:DC%2BD2MXhtVamsbo%3D 15692792 (Pubitemid 40796335)
28. Kogo M, Kano A, Kiuchi Y, Mitamura K, Yoneyama K. Prognostic index for survival in patients after treatment for primary hepatocellular carcinoma. Dig Dis Sci. 2007;52(9):2444-2451
29. OF Couto I Dvorchik BI Carr 2007 Causes of death in patients with unresectable hepatocellular carcinoma Dig Dis Sci 52 3285 3289 10.1007/s10620-007-9750-3 1:STN:280:DC%2BD2srosVemtw%3D%3D 17436087 (Pubitemid 47512544)
30. I Dvorchik BI Carr 2007 A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization Cancer Detect Prev 31 154 160 10.1016/j.cdp.2007.02.003 17416468 (Pubitemid 46669814)
31. PJ Johnson WM Melia MK Palmer, et al. 1981 Relationship between serum alpha-fetoprotein, cirrhosis and survival in hepatocellular carcinoma Br J Cancer 44 502 505 1:STN:280:DyaL38%2Fks1ajuw%3D%3D 6170301
32. CS Wang CL Lin HC Lee, et al. 2005 Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma World J Gastroenterol 11 6115 6119 1:CAS:528:DC%2BD28XhsVentLs%3D 16273636
33. BI Carr F Kanke M Wise, et al. 2007 Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States Dig Dis Sci 52 776 782 10.1007/s10620-006-9541-2 1:CAS:528:DC%2BD2sXhslWju74%3D 17253135 (Pubitemid 46303076)
34. H Toyoda T Kumada Y Osaki, et al. 2007 Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma Hepatol Res 37 S166 S171 10.1111/j.1872-034X.2007. 00181.x 1:CAS:528:DC%2BD2sXhtlCns7jL 17877479
35. ML Volk JC Hernandez GL Su, et al. 2007 Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3 Cancer Biomark 3 79 87 1:CAS:528:DC%2BD2sXotFahtL0%3D 17522429
36. K Shirabe S Itoh T Yoshizumi, et al. 2007 The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin J Surg Oncol 95 235 240 10.1002/jso.20655 1:CAS:528: DC%2BD2sXjvVSjsrg%3D 17323337 (Pubitemid 46310016)
37. M Capurro IR Wanless M Sherman, et al. 2003 Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 89 97 10.1016/S0016-5085(03)00689-9 1:CAS:528:DC%2BD3sXmtVWqtbk%3D 12851874 (Pubitemid 36799110)
38. JT Feng YK Liu HY Song, et al. 2005 Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis Proteomics. 5 4581 4588 10.1002/pmic.200401309 1:CAS:528:DC%2BD2MXht12nt7vM 16240287 (Pubitemid 41739935)
39. L Di Tommaso G Franchi YN Park, et al. 2007 Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis Hepatology 45 725 734 10.1002/hep.21531 1:CAS:528:DC%2BD2sXjs1Gku78%3D 17326147 (Pubitemid 46450624)
40. J Kim SS Ki SD Lee, et al. 2006 Elevated plasma osteopontin levels in patients with hepatocellular carcinoma Am J Gastroenterol 101 2051 2059 10.1111/j.1572-0241.2006.00679.x 1:CAS:528:DC%2BD28XhtVyisLzI 16848813 (Pubitemid 44337631)
41. JS Lee IS Chu J Heo, et al. 2004 Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling Hepatology 40 667 676 10.1002/hep.20375 1:CAS:528:DC%2BD2cXot1OrtLw%3D 15349906 (Pubitemid 39265589)
42. W Sun B Xing Y Sun, et al. 2007 Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues Mol Cell Proteomics. 6 1798 1808 10.1074/mcp.M600449-MCP200 1:CAS:528:DC%2BD2sXht1WksbvM 17627933 (Pubitemid 350031681)
43. HL Jia QH Ye LX Qin, et al. 2007 Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma Clin Cancer Res 13 1133 1139 10.1158/1078-0432.CCR-06-1025 1:CAS:528:DC%2BD2sXhvF2hsLs%3D 17317821 (Pubitemid 46424052)
44. TC Poon TT Yip AT Chan, et al. 2003 Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes Clin Chem 49 752 760 10.1373/49.5.752 1:CAS:528: DC%2BD3sXjsVahs7Y%3D 12709366 (Pubitemid 36513254)
45. AS Budhu B Zipser M Forgues, et al. 2005 The molecular signature of metastases of human hepatocellular carcinoma Oncology 69 Suppl 1 23 27 10.1159/000086628 1:CAS:528:DC%2BD2MXhtVymt73P 16210873 (Pubitemid 41433538)
46. P Kaposi-Novak JS Lee L Gomez-Quiroz, et al. 2006 Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype J Clin Invest 116 1582 1595 10.1172/JCI27236 1:CAS:528:DC%2BD28XlsFWruro%3D 16710476 (Pubitemid 43911012)
47. CM Lo H Ngan WK Tso, et al. 2002 Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 1164 1171 10.1053/jhep.2002.33156 1:CAS:528: DC%2BD38XktF2hu7w%3D 11981766 (Pubitemid 34454013)